The Technical Analyst
Relmada Therapeutics Inc [RLMD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Relmada Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-8.12% $4.30
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 129.75 mill |
| EPS: | -3.28 |
| P/E: | -1.310 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 30.17 mill |
| Avg Daily Volume: | 0.214 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.310 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.22x |
| Company: PE -1.310 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.136 (-96.84%) $-4.16 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.80 - 4.80 ( +/- 11.53%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-31 | Traversa Sergio | Buy | 27 460 | Common Stock |
| 2024-01-30 | Traversa Sergio | Buy | 40 999 | Common Stock |
| 2024-01-29 | Traversa Sergio | Buy | 31 541 | Common Stock |
| 2024-01-31 | Shenouda Maged | Buy | 6 875 | Common Stock |
| 2024-01-30 | Shenouda Maged | Buy | 15 000 | Common Stock |
| INSIDER POWER |
|---|
| 66.71 |
| Last 97 transactions |
| Buy: 7 635 369 | Sell: 1 906 109 |
Forecast:
16:00 - $4.30
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.30
Forecast 2: 16:00 - $4.30
Forecast 3: 16:00 - $4.30
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.30 (-8.12% ) |
| Volume | 0.0861 mill |
| Avg. Vol. | 0.214 mill |
| % of Avg. Vol | 40.17 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RLMD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.18 | N/A | Active |
|---|
RLMD
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Latest Press Releases
2024-03-19 16:15:00 - Press Release
Relmada Therapeutics Provides Corporate Update And Reports Fourth Quarter And Full-year 2023 Financial Results
Coral gables, fla. , march 19, 2024 /prnewswire/ -- relmada therapeutics, inc. (nasdaq: rlmd), a late-stage biotechnology company addressing diseases of the central nervous system (cns), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended december 31, 2023.
2024-03-12 07:30:00 - Press Release
Relmada Therapeutics To Report Fourth Quarter And Full-year 2023 Financial Results And Host Conference Call And Webcast On March 19, 2024
Coral gables, fla. , march 12, 2024 /prnewswire/ -- relmada therapeutics, inc. (nasdaq: rlmd), a late-stage biotechnology company addressing diseases of the central nervous system (cns), today announced that it will report its financial results for the fourth quarter and full-year ended december 31, 2023 after the market close on tuesday, march 19, 2024.
2024-03-05 07:30:00 - Press Release
Relmada Therapeutics To Participate In The Leerink Partners Global Biopharma Conference
Coral gables, fla. , march 5, 2024 /prnewswire/ -- relmada therapeutics, inc. (nasdaq: rlmd), a late-stage biotechnology company addressing diseases of the central nervous system (cns), today announced that sergio traversa, chief executive officer, and maged shenouda, chief financial officer will participate in the leerink partners global biopharma conference in one-on-one investor meetings, taking place march 11-13, 2024, in miami beach, florida.
2024-01-04 07:30:00 - Press Release
Relmada Therapeutics Provides Corporate Update
Company well-positioned for a pivotal 2024 with multiple key clinical development milestones anticipated relmada's strong balance sheet to support the company through all of 2024's expected critical catalysts coral gables, fla. , jan. 4, 2024 /prnewswire/ -- relmada therapeutics, inc. (nasdaq: rlmd), a late-stage biotechnology company addressing diseases of the central nervous system (cns), today provided a corporate update, highlighted the company's key 2023 accomplishments and outlined its anticipated 2024 clinical development milestones.
2023-11-03 07:30:00 - Press Release
Relmada Therapeutics To Report Third Quarter 2023 Financial Results And Host Conference Call And Webcast On November 8, 2023
Coral gables, fla. , nov. 3, 2023 /prnewswire/ -- relmada therapeutics, inc. (nasdaq: rlmd), a late-stage biotechnology company addressing diseases of the central nervous system (cns), today announced that it will report its financial results for the third quarter ended september 30, 2023 after the market close on wednesday, november 8, 2023.
Latest News
2024-03-12 07:30:00 - PRNewsWire
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.
2023-11-09 02:56:01 - Seeking Alpha
Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2023 Results Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Cedric O'Gorman - Chief Medical Officer Conference Call Participants Basma Radwan - SVB Leerink Charles Wang - Mizuho Securities Dina Elmonshed - Jefferies Operator Good afternoon, ladies and gentlemen. And welcome to Relmada Therapeutics, Inc. Third Quarter 2023 Earnings Conference Call.
2023-11-03 07:30:00 - PRNewsWire
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
CORAL GABLES, Fla. , Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2023 after the market close on Wednesday, November 8, 2023.
2023-10-13 19:50:09 - Seeking Alpha
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying efficacy appears robust, consistently reporting treatment responses comparable to approved antidepressants. Ongoing Phase 3 trials, RELIANCE-II and RELIGHT, have amended protocols to control placebo, which should allow REL-1017 to demonstrate efficacy, with readouts in mid-2024 and year-end 2024.
2023-10-11 08:31:00 - PRNewsWire
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic dysfunction-associated steatotic liver disease ( MAS LD) without detrimental CNS effects Mechan ism of action of psilocybin distinct from that of GLP-1 drugs and could be compl e mentary Company intends to initiate the single-ascending dose Phase 1 trial in patients in early 2024 CORAL GABLES, Fla. , Oct. 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that new preclinical data on its novel psilocybin will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023, being held November 10-14, 2023, in Boston, MA.
2023-10-06 07:30:00 - PRNewsWire
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
CORAL GABLES, Fla. , Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
2023-09-21 15:02:08 - Zacks Investment Research
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
2023-09-01 18:53:42 - Seeking Alpha
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim analysis could result in an early stoppage, it isn't a guarantee but could enhance the run up effect as traders take positions early. RLMD has cash to reach the readouts from both RELIANCE II and RELIGHT, but that doesn't mean it wouldn't take advantage of any run up to raise more.
2023-06-08 07:30:00 - PRNewsWire
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
CORAL GABLES, Fla. , June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the Goldman Sachs Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Wednesday, June 14, 2023, at 3:20pm PT / 6:20pm ET in Dana Point, CA.
2023-06-02 07:30:00 - PRNewsWire
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
CORAL GABLES, Fla. , June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O'Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY.